These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 19482012)

  • 1. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
    Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
    Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia.
    Pichat P; Bergis OE; Terranova JP; Urani A; Duarte C; Santucci V; Gueudet C; Voltz C; Steinberg R; Stemmelin J; Oury-Donat F; Avenet P; Griebel G; Scatton B
    Neuropsychopharmacology; 2007 Jan; 32(1):17-34. PubMed ID: 16936709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
    Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
    J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia.
    Kucinski A; Syposs C; Wersinger S; Bencherif M; Stachowiak MK; Stachowiak EK
    Schizophr Res; 2012 Apr; 136(1-3):82-7. PubMed ID: 22285656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.
    Lieberman JA; Dunbar G; Segreti AC; Girgis RR; Seoane F; Beaver JS; Duan N; Hosford DA
    Neuropsychopharmacology; 2013 May; 38(6):968-75. PubMed ID: 23303043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha7 neuronal nicotinic receptors as targets for novel therapies to treat multiple domains of schizophrenia.
    Kucinski AJ; Stachowiak MK; Wersinger SR; Lippiello PM; Bencherif M
    Curr Pharm Biotechnol; 2011 Mar; 12(3):437-48. PubMed ID: 21133847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats.
    Callahan PM; Terry AV; Tehim A
    Psychopharmacology (Berl); 2014 Sep; 231(18):3695-706. PubMed ID: 24595504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of α7 nicotinic acetylcholine receptor agonists on antipsychotic efficacy in a preclinical mouse model of psychosis.
    Kohlhaas KL; Bitner RS; Gopalakrishnan M; Rueter LE
    Psychopharmacology (Berl); 2012 Apr; 220(4):823-33. PubMed ID: 22038534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (2S,3R)-N-[2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a selective α7 nicotinic acetylcholine receptor agonist, for the treatment of cognitive disorders.
    Mazurov AA; Kombo DC; Hauser TA; Miao L; Dull G; Genus JF; Fedorov NB; Benson L; Sidach S; Xiao Y; Hammond PS; James JW; Miller CH; Yohannes D
    J Med Chem; 2012 Nov; 55(22):9793-809. PubMed ID: 23126648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LL-00066471, a novel positive allosteric modulator of α7 nicotinic acetylcholine receptor ameliorates cognitive and sensorimotor gating deficits in animal models: Discovery and preclinical characterization.
    Verma MK; Goel RN; Bokare AM; Dandekar MP; Koul S; Desai S; Tota S; Singh N; Nigade PB; Patil VB; Modi D; Mehta M; Gundu J; Walunj SS; Karche NP; Sinha N; Kamboj RK; Palle VP
    Eur J Pharmacol; 2021 Jan; 891():173685. PubMed ID: 33127363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α7 nicotinic receptor agonist and positive allosteric modulators differently improved schizophrenia-like cognitive deficits in male rats.
    Unal G; Sirvanci S; Aricioglu F
    Behav Brain Res; 2021 Jan; 397():112946. PubMed ID: 33011186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.
    Barak S; Arad M; De Levie A; Black MD; Griebel G; Weiner I
    Neuropsychopharmacology; 2009 Jun; 34(7):1753-63. PubMed ID: 19158670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
    Wishka DG; Walker DP; Yates KM; Reitz SC; Jia S; Myers JK; Olson KL; Jacobsen EJ; Wolfe ML; Groppi VE; Hanchar AJ; Thornburgh BA; Cortes-Burgos LA; Wong EH; Staton BA; Raub TJ; Higdon NR; Wall TM; Hurst RS; Walters RR; Hoffmann WE; Hajos M; Franklin S; Carey G; Gold LH; Cook KK; Sands SB; Zhao SX; Soglia JR; Kalgutkar AS; Arneric SP; Rogers BN
    J Med Chem; 2006 Jul; 49(14):4425-36. PubMed ID: 16821801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D; Lingenhoehl K; Olpe HR; Vassout A; Gentsch C; Chaperon F; Nozulak J; Enz A; Bilbe G; McAllister K; Hoyer D
    Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
    Marquis KL; Comery TA; Jow F; Navarra RL; Grauer SM; Pulicicchio C; Kelley C; Brennan JA; Roncarati R; Scali C; Haydar S; Ghiron C; Terstappen GC; Dunlop J
    Psychopharmacology (Berl); 2011 Dec; 218(4):635-47. PubMed ID: 21643676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia.
    McLean SL; Grayson B; Idris NF; Lesage AS; Pemberton DJ; Mackie C; Neill JC
    Eur Neuropsychopharmacol; 2011 Apr; 21(4):333-43. PubMed ID: 20630711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction.
    Cincotta SL; Yorek MS; Moschak TM; Lewis SR; Rodefer JS
    Curr Opin Investig Drugs; 2008 Jan; 9(1):47-56. PubMed ID: 18183531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders.
    Roncarati R; Scali C; Comery TA; Grauer SM; Aschmi S; Bothmann H; Jow B; Kowal D; Gianfriddo M; Kelley C; Zanelli U; Ghiron C; Haydar S; Dunlop J; Terstappen GC
    J Pharmacol Exp Ther; 2009 May; 329(2):459-68. PubMed ID: 19223665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
    Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
    Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alpha7 nicotinic acetylcholine receptor agonists on attentional set-shifting impairment in rats.
    Jones KM; McDonald IM; Bourin C; Olson RE; Bristow LJ; Easton A
    Psychopharmacology (Berl); 2014 Feb; 231(4):673-83. PubMed ID: 24057763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.